Previous Close | 0.8637 |
Open | 0.8640 |
Bid | 0.8300 x 1400 |
Ask | 0.8758 x 1300 |
Day's Range | 0.8300 - 0.8700 |
52 Week Range | 0.5820 - 4.6500 |
Volume | |
Avg. Volume | 600,014 |
Market Cap | 42.62M |
Beta (5Y Monthly) | 1.65 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.4600 |
Earnings Date | May 16, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.63 |
Subscribe to Yahoo Finance Plus to view Fair Value for AGTC
GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that Sue Washer, President & Chief Executive Officer, Jon Lieber, Chief Financial Officer, and Susan Schneider, Chief Medic
Applied Genetic Technologies Corp (NASDAQ: AGTC) reported three-month interim data from its ongoing Phase 2 Skyline trial of AGTC-501 for X-linked retinitis pigmentosa (XLRP), an inherited condition causing progressive vision loss in boys and young men. AGTC-501 is a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene. There were robust improvements in visual sensitivity, the trial's primary efficacy endpoint, in multiple patients three months after dosing, with
– 62.5% of Patients in Dose Group B Were Responders for Improvements in Visual Sensitivity, the Study’s Primary Efficacy Endpoint – – Continued Strong Safety Data – – Robust Safety and Efficacy Data Consistent with Previously Reported Results from the Phase 1/2 Trial in XLRP – – Company to Host Conference Call to Review Data on May 17 at 8:00 a.m. ET – GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stag